Experimental Methods. All reagents were purchased from commercial sources and used as received unless noted. Ligand and CuSO 4 or Zn(OAc) 2 solutions were prepared in MilliQ water and diluted to the desired concentration using buffer (15 mM) phosphate buffer with NaCl (15 mM). Each experiment was performed in triplicate with a peptide to copper to ligand ratio of 1:2:4 respectively. Physical Methods. A Molecular Devices Spectra Max MS microplate reader was employed to obtain the turbidity and UV-Vis results. Fluorescence measurements were recorded on a Varian Cary Eclipse with voltage set to high, and the instrument was set to record the average of three scans. HR-MS was performed using the Agilent 6224 Accurate-Mass Time-Of-Flight (TOF) MS. A Varian Mercury 300 was utilized to obtain the NMR spectra in deuterated solvents as specified in the sections below.
Scheme S2. Synthetic route to 4-Benzyloxy-2,6-bis(chloromethyl)pyridine (7) .
Diethyl-4Hydroxypyridine-2,6-dicarboxylate (4). Protection of the Chelidamic acid was accomplished according to Kazufumi et al. 2 Chelidamic acid (5.0 g, 27.3 mmol) was dissolved in anhydrous ethanol (200 mL), and 5 mL of SOCl 2 . The solution was heated at reflux (80 °C) for 6 h and evaporated to dryness. Toluene was added to the resulting residue, 50 mL × 2. Diethyl ether and water, 100 mL each, was added to the flask containing the residue. The flask was capped and shaken three times; upon which a white crystalline solid became suspended between these layers. The white crystalline solid was filtered and dried over vacuum with no further purification necessary. Yield: 5.56 g, (70%). 1 H NMR (CDCl 3 ), δ: 1.38 (t, CH 2 CH 3 , 6H), 4.38 (q, CH 2 CH 3 , 4H), 7.43 (s, py H, 2H), 9.2 (s, OH, 1H).
13 C NMR (CDCl 3 ) δ: 14. 2, 18.3, 58.3, 63.0, 118.0, 163.5 .
Diethyl 4-(Benzyloxy)pyridine-2,6-dicarboxylate (5).
Compound 5 was also produced using the methods of Froidevaux. 3 Compound 4 (5.0 g, 20.9 mmol) was dissolved in dry acetonitrile (150 mL) followed by sequential addition of K 2 CO 3 (4.5 g, 32.8 mmol) and benzyl bromide (20.9 mmol, 2.4 mL). The reaction mixture was heated at reflux (82 °C) under N 2 , for 12 h. The reaction mixture was cooled to room temperature, filtered to remove the inorganic salts, and evaporated to dryness. The oily residue was crystallized from hot hexane to yield 5 as a white solid. Yield 7.55 g (94%) . 1 H NMR (CDCl 3 ), δ: 1.43 (t, CH 2 CH 3 , 6H), 4.43 (q, CH 2 CH 3 , 4H), 5.22 (s, CH 2 Bz, 2H), 7.39 (m, Ar H, 5H), 7.87 (s, py H, 2H) 13 C NMR (CDCl 3 ) δ: 14.1, 62. 4, 70.7, 114.6, 127.7, 128.7, 128.8, 135.0, 150.0, 164.8, and 166.6. 4-(Benzyloxy)-2,6-bis(hydroxymethyl)pyridine (6) . Reduction of the esters was performed according to Busto 3 , with a slight modification of the procedure, as CH 2 Cl 2 was used in place of ethyl acetate to extract the product. The previous product 5 (5.0 g, 20.9 mmol) was dissolved in absolute EtOH (320 mL) and then NaBH 4 (3.80 g, 100 mmol) was added in one portion. The mixture was heated to 40 °C and stirred for 24 h. The resulting mixture was quenched with H 2 O (50 mL) and filtered to remove the boric acid precipitate. Next, the bulk of the ethanol was removed under reduced pressure and the resulting aqueous extracted with CH 2 Cl 2 (3 × 100 mL). It should be noted if there is difficulty in visible separation of the two layers, the addition of more water is necessary for ideal separation. The organic phases were combined and dried over sodium sulfate to yield 6 as a white, crystalline solid with no further purification necessary. Yield 3.56 g (95%). 1 H NMR (DMSO), δ: 4.42 (s, CH 2 OH, 4H), 5.14 (s, CH 2 OH, 2H), 5.36 (s, CH 2 C 6 H 5 , 2H), 6.90 (s, py H, 2H), 7.30 (m, Ar H, 5H) .
13 C NMR (CDCl 3 ) δ: 62. 6, 67.6, 103.3, 126.3, 126.7, 127.1, 135.0, 161.7, 164.4. 4-Benzyloxy-2,6-bis(chloromethyl)pyridine (7). The reported method by Chessa 4 was used for synthesis of the alkyl halide with MeOH used instead of EtOH for recrystallization resulting in higher yields in our hands. Thionyl chloride (22 mL, 234 mmol) was slowly added to 6 (2.37 g, 9.6 mmol), the clear solution was heated under reflux at 60°C for 4 h, cooled to room temperature and excess thionyl chloride was removed under reduced pressure. The residue was neutralized with a cold solution of 10% Na 2 CO 3 . The beige solid was filtered and washed thoroughly with cold water, and recrystallized from hot methanol to give 7 as white, crystalline needles. Yield, 2.35 g (90% 46.7, 70.4, 109.0, 127.9, 128.8, 129.0, 135.8, 158.2, 168.3. Scheme S3. Macrocyclization and deprotection reactions used to produce 2.
12-Benzyloxy-3,6,9-tris(2-nitrobenzenesulfonyl)-3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-triene (8). Macrocyclization was done according to , also with a modification of the procedure due the observation that the fully protected macrocyclic product is not soluble in CH 2 Cl 2 . A solution of 7 (2.22, 7.8 mmol) in anhydrous DMF (125 mL) was added drop wise over 4 h, under N 2, to a stirred solution of 3 (5.19 g, 7.8 mmol) and Na 2 CO 3 (3.8 g, 31.2 mmol) in anhydrous DMF (125 mL) at 100 °C. The bright yellow solution was heated at reflux overnight, and the solvent was removed under reduced pressure to give an orange solid. The orange solid was taken up in CH 2 Cl 2 , filtered, washed with 0.1 M NaOH (200 mL), washed with water (2 × 100 mL) followed by diethyl ether (2 × 100 mL) to give 8 as a fine, powdery and bright yellow solid. Yield 5.53 g (80%) . 1 H NMR (DMSO) δ: 3.47 (t, 4H), 3.73 (t, 4H), 4.53 (s, 4H), 5.16 (s, 2H), 6.98 (s, 2H), 7.35 (m, 5H), 7.83 (m, 12 H) .
13 C NMR (DMSO) δ: 31. 2, 46.3, 54.9, 70.6, 111.2, 124.4, 124.6, 128.0, 128.7, 129.0, 131.1, 131.5, 132.3, 134.2, 156.6 , with no modification. Thiophenol (4 mL, 38.2 mmol) was added to a stirred solution of 8 (5.53 g, 6.3 mmol) and Na 2 CO 3 (8.0 g, 75 mmol) in anhydrous DMF (80 mL). The dark orange solution was stirred overnight at room temperature. The solvent was evaporated to give an oily orange residue which was triturated with aqueous HCl (1M). The yellow aqueous phase was extracted with diethyl ether (2 × 100 mL), and the organic layer was discarded. The yellow aqueous solution was adjusted to pH 12 with NaOH, and concentrated under reduced pressure. The yellow solid was taken up in CH 2 Cl 2 (200 mL), dried over sodium sulfate, and solvent removed under reduced pressure to give a yellow oil. Diethyl ether was added to the yellow oil, followed by drop wise addition of concentrated HCl until precipitation of a yellowish solid occurred. The solution containing the precipitate was filtered to give 9 as a fine and powdery light yellow solid. Yield 3.30 g, (75%). 3,6,9,15-tetraazabicyclo[9.3.1]penta-deca-1(15),11,13-trien-13-ol (2). Debenzylation was performed as stated by Mochizuki 7 , with no change in procedure as the authors note that the HCl salt is necessary for General procedure for metal complexation with (2). Metal complexes were prepared by dissolving 50 mg of 2 in 2 mL of water, and the pH of the solution was adjusted to 7.0 with concentrated NaOH. Perchlorate salts of zinc or copper were added to the ligand in a ratio of 1:1 and stirred for 2 days at room temperature. Next, the solvent was removed and the complexes were taken up in a minimum amount of methanol. The resulting solutions were filtered through a syringe filter. ESI-MS and UV-Vis were used to indicate complex formation of all solutions. DPPH Assay. DPPH stock solution was prepared by dissolving 25 mg in 100 mL of absolute EtOH. The working radical solution was prepared by dilution with absolute EtOH to an absorbance of 1.3 ± 0.002 units at 515 nm.
8 Stock solutions of BHT (positive control), 1 and 2 were dissolved in 95% EtOH to a concentration of 5mM, and serial dilutions were done in 95% EtOH to reach the desired concentrations. For the analysis, 2 mL of 95 % EtOH (control) BHT, or ligands (625 µM-37.5 μM) were combined with 2 mL of the DPPH working solution and incubated in the dark for 24 hours. Analysis of the solutions was performed as follows: 1 mL of the sample solution was diluted with 1 mL of absolute EtOH in a cuvette, shaken for 30 s and absorbance measured at 515 nm. Analysis of each sample was performed in triplicate. EtOH (95 %) was used as a control in this experiment, and all data were normalized to the average (n = 3) absorbance of this sample. In addition, 1 mL of DPPH working solution (incubated for 24 hours) was diluted with 1 mL of absolute EtOH, repeated in triplicate, and the absorbance was normalized to the average of the control (95% EtOH) absorbance value.
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Preparation of A 1-40 stock. Synthetic Beta Amyloid 1-40 peptide was purchased from Twenty-First Century Biochemicals. A peptide stock solution was prepared by dissolving 1.9 mg of A 1-40 in 1 mL of buffer, followed by NaOH (20 mM, 300 L). The solution was sonicated for one minute then adjusted to pH 7.4 using HCl (0.5 M, ~10.5 L). The solution was sonicated for another minute and diluted to 200 M using MQ water. Turbidity Studies. Two separate turbidity studies (absorbance at 405 nm) were performed using amyloid, copper or zinc, and ligands one to determine disaggregation capability and another to determine preventive capability of copper induced beta amyloid formation. Turbidity studies were repeated with HEPES Buffer (0.02 HEPES, 0.154 M NaCl, pH=7.4) giving identical results.
(a) Disaggregation. Zinc (II) acetate or copper (II) sulfate solution (400 M, 40 L) was added to a solution of A 40 (200 M, 40 L) and incubated at 37 °C for one day. After incubation the ligand stock solutions were added (800 M, 40 L) to aggregated peptide solution and incubated for a further 12 hours at 37 °C. For analysis of turbidity, 20 L sample aliquots were diluted with buffer (180 L) and absorbance recorded using a Microplate reader (Softmax Pro M5). The value of the blank absorbance was subtracted from each sample value.
(b) Preventative. Ligand stock solutions (800 M, 40 L) were added to a solution of A 40 (200 M, 40 L) and incubated for five minutes at room temperature followed by addition of Zn(OAc) 2 or CuSO 4 (400 M, 40 L). All samples were incubated at 37 °C for one day. Absorbance measurements were carried out in the same manner as described above. Tyrosine Fluorescence. Tyrosine fluorescence studies were carried out on samples used for the turbidity experiments. For sample preparation, 50 L of sample was diluted with 270 L of buffer and agitated for 30 s. Excitation and emission values utilized were 278 and 305 nm, respectively. 9 DCFH-DA Assay. Fibroblasts obtained from a 30 year old FRDA patient from The Coriell Institute (Camden, NJ, USA) were kept in Dulbecco's Modified Eagle Medium (DMEM; ThermoScientific, Waltham, MA, USA) with 10% charcoal-stripped fetal bovine serum (FBS; ThermoScientific), 1% GlutaMAX (ThermoScientific) and 1% penicillinstreptomycin (Invitrogen, Carlsbad, CA, USA) at 37 o C, 5% CO 2 and 90% humidity. HT-22 cells were prepared in a similar manner. The FRDA or HT-22 cells were plated at 5,000 cells per well on a 96-well plate, then treated for 12 hours with either ligands (various concentrations) and/or BSO (1mM). After 12 hours of treatment the media was removed from each well of the 96-well plate, and 100 µL of a 1 µM 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA; AnaSpec Inc., Fremont, CA, USA) in phosphate buffer (PBS) was added to each well. The plates were returned to a 37 o C incubator for 20 minutes, then each well was washed three times with PBS and the plate was read on a Tecan Infinite M200 plate reader with an absorbance of 495 nm and an emission of 529 nm, respectively.
Calcein AM Cell Viability Assay. FRDA cells were plated on a 96-well plate at a density of 3,000 cells per well, then treated with ligands (various concentrations) and/or BSO (1mM). After 48 hours of BSO and ligand treatment, the media was removed, and 1 g/mL Calcein AM (CalBiochem, San Diego, CA, USA) in phosphate buffer pH 7.2 (PBS; Fisher Scientific, Pittsburg, PA, USA) was added to each well and the plate was incubated for 10 minutes at 37 o C. Cell viability was determined with a Tecan Infinite M200 plate reader with an excitation of 490 nm and emission of 520 nm. Legend for Tables S1 and S2 . Figure S1 . Cyclic voltammograms of Cu(1) and Cu (2), [3 mM] , in phosphate buffer at pH = 7.4, referenced to a Ag/AgCl electrode. Scan rate = 100 mV/s. *The oxidation peak of Cu (2) around -100 mV is ligand based. Turbidity Studies: Copper (II) or zinc (II) ion addition to a solution of amyloid 1-40 results in a turbid solution which scatters light with a consequential increased absorbance signal using absorption spectrophotometry. 25, 27 Turbidity results show that incubation of 1 or 2 with Aβ 1-40 prior to addition of Cu II or Zn II prevents formation of aggregations compared to amyloid incubated with metal-ions alone. These studies were also carried out with other N-heterocylic amines and open chain chelators which have been studied by others and show that our ligands are equally effective in terms of anti-aggregate activity. 25 Moreover, amyloid aggregates formed by metal ion coincubation can be disaggregated by the addition of 1 or 2. 33 Chelators 1 and 2 are equally effective in preventing signal decrease and reconstituting the Tyr-10 signal for both types of metal induced quenching. These results are compared to macrocyclic and open-chain chelators cyclam and EDTA, which show an equivalent capacity. These results are consistent with the turbidity studies suggesting that the Tyr-10 signal can be used to follow the aggregates formation as well. 
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